{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:26:21Z","timestamp":1793330781157,"version":"4.5.0"},"reference-count":52,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872179"],"award-info":[{"award-number":["81872179"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Objectives: As diagnosis and treatment guidelines for bone sarcomas continue updating, it is important to examine whether, when, and which kinds of patients have had a survival improvement over the last four decades. Methods: This cohort study included 9178 patients with primary bone and joint sarcomas from 1 January 1980 to 31 December 2018 using data from Surveillance, Epidemiology and End Results (SEER)-9 Registries. The follow-up period was extended to November 2020. Patients were divided by decade into four time periods: 1980\u20131989, 1990\u20131999, 2000\u20132009, and 2010\u20132018. The primary endpoint was bone sarcomas-specific mortality (CSM). The 5-year bone sarcomas-specific survival (CSS) rate was determined stratified by demographic, neoplastic, temporal, economic, and geographic categories. The associations between time periods and CSM were examined using a multivariable Cox regression model, with reported hazard ratio (HR) and 95% confidence interval (CI). Results: The 5-year CSS rate for bone sarcomas was 58.7%, 69.9%, 71.0%, and 69.2%, in the 1980s, 1990s, 2000s, and 2010s, respectively. Older age, male gender, tumor sites at pelvic bones, sacrum, coccyx and associated joints, as well as vertebral column, osteosarcoma and Ewing tumor, and residence in non-metropolitan areas were independently associated with higher CSM risk. After adjusting for the covariates above, patients in the 1990s (HR = 0.74, 95% CI = 0.68\u20130.82), 2000s (HR = 0.71, 95% CI = 0.65\u20130.78), and 2010s (HR = 0.68, 95% CI = 0.62\u20130.76) had significantly lower CSM risks than patients in the 1980s. However, patients in the 2000s and 2010s did not have lower CSM risks than those in the 1990s (both p &gt; 0.05). Conclusions: Although bone sarcomas survival has significantly improved since 1990, it almost halted over the next three decades. Bone sarcomas survival should improve over time, similar to common cancers. New diagnostic and therapeutic strategies such as emerging immune and targeted agents are warranted to overcome this survival stalemate.<\/jats:p>","DOI":"10.3390\/cancers13215381","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T22:00:23Z","timestamp":1635372023000},"page":"5381","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Trends in Tumor Site-Specific Survival of Bone Sarcomas from 1980 to 2018: A Surveillance, Epidemiology and End Results-Based Study"],"prefix":"10.3390","volume":"13","author":[{"given":"Xianglin","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou 646000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Ye","sequence":"additional","affiliation":[{"name":"Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengwang","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wending","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangbai","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9178-0687","authenticated-orcid":false,"given":"Wangjun","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"key":"ref_1","unstructured":"National Complrehensive Cancer Network (2013). Bone cancer. J. Natl. Compr. Cancer Netw., 11, 688\u2013723."},{"key":"ref_2","unstructured":"SEER (2021, August 25). Cancer Stat Facts: Bone and Joint Cancer, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/bones.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"103340","DOI":"10.1016\/j.critrevonc.2021.103340","article-title":"Osteosarcoma, chondrosarcoma and Ewing sarcoma: Clinical aspects, biomarker discovery and liquid biopsy","volume":"162","author":"Aran","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_4","first-page":"22","article-title":"Bone Tumors: Primary Bone Cancers","volume":"493","author":"Keil","year":"2020","journal-title":"FP Essent."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/CCO.0000000000000456","article-title":"Current questions in bone sarcomas","volume":"30","author":"Strauss","year":"2018","journal-title":"Curr. Opin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1001\/jamaoncol.2014.161","article-title":"Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010","volume":"1","author":"Zeng","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/ijc.30766","article-title":"Why is colon cancer survival improving by time? A nationwide survival analysis spanning 35 years","volume":"141","author":"Snaebjornsson","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Wang, S., Sun, T., Sun, H., Li, X., Li, J., Zheng, X., Mallampati, S., Sun, H., Zhou, X., and Zhou, C. (2017). Survival improvement in patients with non-small cell lung cancer between 1983 and 2012: Analysis of the Surveillance, Epidemiology, and End Results database. Tumour. Biol., 39.","DOI":"10.1177\/1010428317691677"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ajh.26156","article-title":"Acute lymphoblastic leukemia: A population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980\u20132017","volume":"96","author":"Sasaki","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/cncr.33458","article-title":"De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"key":"ref_11","first-page":"420","article-title":"National Comprehensive Cancer Network. Bone cancer","volume":"5","author":"Biermann","year":"2007","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"688","DOI":"10.6004\/jnccn.2010.0051","article-title":"National Comprehensive Cancer Network Bone Cancer Panel. Bone cancer","volume":"8","author":"Biermann","year":"2010","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.6004\/jnccn.2017.0017","article-title":"NCCN Guidelines Insights: Bone Cancer, Version 2.2017","volume":"15","author":"Biermann","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0140-6736(14)62038-9","article-title":"Global surveillance of cancer survival 1995-2009: Analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2)","volume":"385","author":"Allemani","year":"2015","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/cncr.24121","article-title":"Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program","volume":"115","author":"Mirabello","year":"2009","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s11999-016-4779-2","article-title":"Survival in Mesenchymal Chondrosarcoma Varies Based on Age and Tumor Location: A Survival Analysis of the SEER Database","volume":"475","author":"Schneiderman","year":"2017","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Evans, D.R., Lazarides, A.L., Visgauss, J.D., Somarelli, J.A., Blazer, D.G., Brigman, B.E., and Eward, W.C. (2020). Limb salvage versus amputation in patients with osteosarcoma of the extremities: An update in the modern era using the National Cancer Database. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07502-z"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/jso.25701","article-title":"A propensity-score matched analysis of limb salvage vs amputation for osteosarcoma","volume":"120","author":"Traven","year":"2019","journal-title":"J. Surg. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1007\/s00268-016-3500-7","article-title":"Amputation Versus Limb-Salvage Surgery in Patients with Osteosarcoma: A Meta-analysis","volume":"40","author":"Han","year":"2016","journal-title":"World J. Surg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"107611","DOI":"10.1016\/j.pharmthera.2020.107611","article-title":"New insights into molecular and cellular mechanisms of zoledronate in human osteosarcoma","volume":"214","author":"Lu","year":"2020","journal-title":"Pharm. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(16)30096-1","article-title":"Sarcoma Group of UNICANCER.; French Society of Pediatric Oncology (SFCE); French Sarcoma Group (GSF-GETO). Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): A randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Pacquement","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S1470-2045(16)30214-5","article-title":"Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): An open-label, international, randomised controlled trial","volume":"17","author":"Marina","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Spa\u0142ek, M.J., Poleszczuk, J., Czarnecka, A.M., Dudzisz-\u015aled\u017a, M., Napieralska, A., Matysiakiewicz, J., and Rutkowski, P. (2021). Radiotherapy in the Management of Pediatric and Adult Osteosarcomas: A Multi-Institutional Cohort Analysis. Cells, 10.","DOI":"10.3390\/cells10020366"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1001\/jamaoncol.2014.289","article-title":"Alpha Emitter Radium 223 in High-Risk Osteosarcoma: First Clinical Evidence of Response and Blood-Brain Barrier Penetration","volume":"1","author":"Subbiah","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e000635","DOI":"10.1136\/esmoopen-2019-000635","article-title":"223-Radium for metastatic osteosarcoma: Combination therapy with other agents and external beam radiotherapy","volume":"5","author":"Anderson","year":"2020","journal-title":"ESMO Open"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/nrc3838","article-title":"Translational biology of osteosarcoma","volume":"14","author":"Kansara","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2020.12.024","article-title":"Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs","volume":"500","author":"Chen","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e27227","DOI":"10.1002\/pbc.27227","article-title":"Immunotherapy for osteosarcoma: Where do we go from here?","volume":"65","author":"Wedekind","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/med.21557","article-title":"Harnessing the untapped potential of nucleotide-binding oligomerization domain ligands for cancer immunotherapy","volume":"39","author":"Nabergoj","year":"2019","journal-title":"Med. Res. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1080\/14656566.2021.1936499","article-title":"State-of-the-art, approved therapeutics for the pharmacological management of osteosarcoma","volume":"22","author":"Meazza","year":"2021","journal-title":"Expert Opin. Pharm."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Boehme, K.A., Schleicher, S.B., Traub, F., and Rolauffs, B. (2018). Chondrosarcoma: A Rare Misfortune in Aging Human Cartilage? The Role of Stem and Progenitor Cells in Proliferation, Malignant Degeneration and Therapeutic Resistance. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19010311"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/jso.25854","article-title":"Advancing patient age is associated with worse outcomes in low- and intermediate-grade primary chondrosarcoma of the pelvis","volume":"121","author":"Houdek","year":"2020","journal-title":"J. Surg. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/CORR.0000000000000632","article-title":"Does Resection of the Primary Tumor Improve Survival in Patients With Metastatic Chondrosarcoma?","volume":"477","author":"Song","year":"2019","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"E1661","DOI":"10.1097\/BRS.0000000000003694","article-title":"Primary Tumor Resection Prolongs Survival in Spinal Chondrosarcoma Patients With Distant Metastasis","volume":"45","author":"Song","year":"2020","journal-title":"Spine"},{"key":"ref_36","first-page":"6959","article-title":"Clinical Efficacy of Carbon Ion Radiotherapy for Unresectable Chondrosarcomas","volume":"37","author":"Imai","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.7150\/jca.29667","article-title":"Carbon Ion Radiotherapy for Patients with Extracranial Chordoma or Chondrosarcoma\u2014Initial Experience from Shanghai Proton and Heavy Ion Center","volume":"10","author":"Wu","year":"2019","journal-title":"J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jor.24463","article-title":"Survival and Prognosis of Chondrosarcoma Subtypes: SEER Database Analysis","volume":"38","author":"Amer","year":"2020","journal-title":"J. Orthop. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/CCO.0000000000000300","article-title":"Molecular oncogenesis of chondrosarcoma: Impact for targeted treatment","volume":"28","author":"Speetjens","year":"2016","journal-title":"Curr. Opin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2217\/fon-2016-0226","article-title":"Novel therapeutic approaches in chondrosarcoma","volume":"13","author":"Polychronidou","year":"2017","journal-title":"Future Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1470-2045(09)70286-4","article-title":"Ewing\u2019s sarcoma","volume":"11","author":"Balamuth","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1007\/s12094-020-02298-7","article-title":"Precision medicine in Ewing sarcoma: A translational point of view","volume":"22","author":"Gargallo","year":"2020","journal-title":"Clin. Transl. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/CORR.0000000000000962","article-title":"Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing\u2019s Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial","volume":"478","author":"Andreou","year":"2020","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Ahmed, S.K., Robinson, S.I., Arndt, C.A.S., Petersen, I.A., Haddock, M.G., Rose, P.S., and Laack, N.N.I. (2017). Pelvis Ewing sarcoma: Local control and survival in the modern era. Pediatr. Blood Cancer, 64.","DOI":"10.1002\/pbc.26504"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.1990.8.10.1664","article-title":"Multimodal therapy for the management of primary, nonmetastatic Ewing\u2019s sarcoma of bone: A long-term follow-up of the First Intergroup study","volume":"8","author":"Nesbit","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1200\/JCO.2011.41.5703","article-title":"Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: A report from the Children\u2019s Oncology Group","volume":"30","author":"Womer","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1200\/JCO.19.00915","article-title":"High-Dose Chemotherapy Compared with Standard Chemotherapy and Lung Radiation in Ewing Sarcoma with Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008","volume":"37","author":"Dirksen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e27011","DOI":"10.1002\/pbc.27011","article-title":"Recurrence of Ewing sarcoma: Is detection by imaging follow-up protocol associated with survival advantage?","volume":"65","author":"Heinemann","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/CCO.0000000000000502","article-title":"Chordoma: Update on disease, epidemiology, biology and medical therapies","volume":"31","author":"Frezza","year":"2019","journal-title":"Curr. Opin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Obid, P., Fekete, T., Drees, P., Haschtmann, D., Kleinst\u00fcck, F., Loibl, M., and Jeszenszky, D. (2021). Revision surgery for incomplete resection or recurrence of cervical spine chordoma: A consecutive case series of 24 patients. Eur. Spine J.","DOI":"10.1007\/s00586-021-06946-6"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3389\/fonc.2019.00030","article-title":"Molecular Targeted Therapy in the Treatment of Chordoma: A Systematic Review","volume":"9","author":"Meng","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11523-021-00814-5","article-title":"Targeted Therapy for Chordoma: Key Molecular Signaling Pathways and the Role of Multimodal Therapy","volume":"16","author":"Akinduro","year":"2021","journal-title":"Target. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/21\/5381\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:24:43Z","timestamp":1760167483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/21\/5381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":52,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["cancers13215381"],"URL":"https:\/\/doi.org\/10.3390\/cancers13215381","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]}}}